When exploring eye health research, you’ve likely come across the Age-Related Eye Disease Study 2 (AREDS2), a landmark investigation that has shaped how we approach age-related vision problems. But did this influential study examine dry eye syndrome?
Understanding the AREDS2 study
The AREDS2 clinical trial was a comprehensive research initiative launched in 2006 by the National Eye Institute. This multi-centre study enrolled 4,203 participants aged 50 to 85 across 82 clinical sites, specifically focusing on individuals at high risk of developing advanced age-related macular degeneration (AMD).
The study built upon the original AREDS research, which had demonstrated that specific nutritional supplements could reduce the risk of AMD progression. AREDS2 aimed to refine this formula by testing several key modifications.
What AREDS2 actually investigated
The primary objectives of AREDS2 were remarkably specific and focused on two main eye conditions:
Age-related macular degeneration (AMD)
AREDS2 evaluated whether adding lutein and zeaxanthin (plant-derived carotenoids) and omega-3 fatty acids (DHA and EPA) to the original AREDS formula would provide additional protection against AMD progression. The study also examined the effects of removing beta-carotene, which had been linked to increased lung cancer risk in smokers.
Cataracts
Researchers monitored participants for cataract development and progression throughout the five-year study period.
The study concluded that whilst lutein and zeaxanthin offered similar or better benefits than beta-carotene, the addition of omega-3 fatty acids did not significantly reduce AMD progression beyond the original formula.
Did AREDS2 examine dry eye syndrome?
The straightforward answer is no – AREDS2 was not designed to study dry eye syndrome directly. The study’s research protocols, outcome measures, and data collection methods were specifically tailored to assess AMD and cataract progression.
Dry eye syndrome was not listed among the primary or secondary outcomes, and participants were not systematically evaluated for dry eye symptoms or signs during the trial.
The omega-3 connection: Why the confusion exists
The confusion about AREDS2 and dry eye stems from the fact that omega-3 fatty acids – one of the supplements tested in AREDS2 – have been extensively studied for dry eye treatment in other research.
Omega-3 fatty acids and dry eye
Omega-3 fatty acids possess anti-inflammatory properties that theoretically could benefit the ocular surface. Numerous studies have explored this connection:
Early research showed promise:
- Meta-analyses published between 2014 and 2017 suggested that omega-3 supplementation improved tear break-up time and Schirmer’s test results
- Some smaller trials reported improvements in dry eye symptoms with omega-3 supplementation
- The ratio of omega-6 to omega-3 fatty acids in the diet appeared to correlate with dry eye risk.
However, more recent evidence tells a different story:
The Dry Eye Assessment and Management (DREAM) study, published in 2018, provided the most robust evidence to date. This large-scale trial found that 3,000mg of omega-3 fatty acids daily offered no significant benefit over placebo for moderate-to-severe dry eye disease over 12 months.
A 2023 systematic review confirmed these findings, with researchers noting considerable variation in study results and calling for more standardised research approaches.
Why AREDS2 nutrients matter for overall eye health
Even though AREDS2 didn’t study dry eye syndrome, the nutrients it examined play important roles in eye health:
Lutein and zeaxanthin
These carotenoids accumulate in the macula and retina, where they:
- Filter harmful blue light
- Act as antioxidants
- May reduce oxidative stress in retinal tissue
Omega-3 fatty acids (DHA and EPA)
DHA is a structural component of retinal cell membranes and is essential for:
- Retinal cell integrity
- Visual development and function
- Supporting the tear film lipid layer
The current evidence on omega-3 and dry eye
Based on current research, the evidence for omega-3 supplementation in dry eye management remains mixed:
When omega-3 might be beneficial:
- In meibomian gland dysfunction, where they may help improve lipid secretion
- When taken at higher doses (2,000-3,000mg daily) for extended periods
- In combination with other treatments rather than as a standalone therapy
What the UK guidance says
The NIHR evidence review notes that whilst some UK speciality guidelines acknowledge omega-3 fatty acids as “worth a try” for dry eye, they also recognise there is “insufficient evidence” to prove their effectiveness.
Managing dry eye syndrome: Evidence-based approaches
If you’re experiencing dry eye symptoms, several proven treatments are available in the UK:
First-line treatments
- Artificial tears: Available in numerous formulations, these provide symptomatic relief
- Eyelid hygiene: Warm compresses and lid scrubs, particularly for blepharitis-related dry eye
- Environmental modifications: Using humidifiers, taking screen breaks, and reducing air conditioning exposure
Prescription treatments
- Cyclosporine eye drops: Anti-inflammatory medication for chronic dry eye
- Corticosteroid drops: For short-term management of inflammation
- Lifitegrast: A newer anti-inflammatory option
- Autologous serum eye drops: For severe cases
Procedures
- Punctal plugs to reduce tear drainage
- Intense pulsed light therapy for meibomian gland dysfunction
- LipiFlow thermal pulsation treatment
What we can learn from AREDS2
Whilst AREDS2 didn’t study dry eye syndrome, the trial offers valuable lessons:
- Individual nutrients have specific roles: The AREDS2 findings remind us that supplements developed for one condition may not benefit another
- Rigorous research matters: AREDS2’s methodological approach set a gold standard for nutritional supplement studies in ophthalmology
- Supplements aren’t universal solutions: Even nutrients with theoretical benefits require clinical evidence before recommendations can be made
Should you take AREDS2 supplements for dry eye?
If you’re considering AREDS2 supplements specifically for dry eye management, the evidence doesn’t support this approach. AREDS2 formulations are designed for individuals at risk of advanced AMD, not for treating dry eye syndrome.
However, if you have both intermediate or advanced AMD and dry eye syndrome, taking AREDS2 supplements for your AMD is appropriate – just don’t expect them to significantly improve your dry eye symptoms based on current evidence.
The bottom line
AREDS2 was not designed to study dry eye syndrome and provides no direct evidence about supplements for this condition. Whilst the omega-3 fatty acids in AREDS2 have been investigated separately for dry eye treatment, the most robust recent trials have found limited benefit.
For those concerned about AMD, the AREDS2 formula remains an evidence-based recommendation – but for dry eye, other treatments with stronger supporting evidence should be your first consideration.
